Salud financiera de hoja de balance de Catalyst Biosciences

Salud financiera controles de criterios 5/6

Catalyst Biosciences tiene un patrimonio de los accionistas total de $3.5M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $10.0M y $6.4M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$2.23m
Patrimonio	US$3.52m
Total pasivo	US$6.45m
Activos totales	US$9.96m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($5.1M) de HGF2 superan a sus pasivos a corto plazo ($1.8M).

Pasivo a largo plazo: Los activos a corto plazo de HGF2 ($5.1M) superan a sus pasivos a largo plazo ($4.7M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: HGF2 está libre de deudas.

Reducción de la deuda: HGF2 no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: HGF2 tiene suficiente cash runway para 2 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Datos insuficientes para determinar si HGF2 tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.

Salud financiera de hoja de balance de Catalyst Biosciences

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Catalyst Biosciences Announces Update on Letter from Nasdaq Regarding Minimum Bid Price Requirement

Catalyst Biosciences Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Recent updates

Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. (NasdaqCM:CBIO) in a reverse merger transaction.

Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.

Catalyst Biosciences Announces Update on Letter from Nasdaq Regarding Minimum Bid Price Requirement

Full year 2022 earnings released: US$0.26 loss per share (vs US$2.87 loss in FY 2021)

Catalyst Biosciences, Inc. Terminates Grant Blouse from the Position as the Chief Scientific Officer

Inaugural dividend of US$0.24 per share

Insufficient new directors

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)

Catalyst Biosciences Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Insider recently sold €289k worth of stock

Insider recently sold €513k worth of stock

Inaugural dividend of US$1.43 per share

Catalyst Biosciences, Inc. Declares Special One-Time Cash Dividend, Payable on September 20, 2022

Catalyst Biosciences, Inc. Announces Dismissal of Jds1 Litigation

Second quarter 2022 earnings released: EPS: US$1.64 (vs US$0.64 loss in 2Q 2021)

Forecast to breakeven in 2022

JEC II Associates, LLC Reaches an Agreement Catalyst Biosciences

JDS1 LLC Issues an Investor Presentation to Shareholders of Catalyst Biosciences Inc

JDS1, LLC Provides Information to the Shareholders

JEC II Associates Engages in Discussions with Catalyst Biosciences

Insider recently bought €891k worth of stock

JDS1, LLC Provides Information to the Shareholders

Catalyst Biosciences, Inc., Annual General Meeting, Aug 15, 2022

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

First quarter 2022 earnings released: US$0.46 loss per share (vs US$0.79 loss in 1Q 2021)

JDS1 Files a Complaint against Catalyst Biosciences

JDS1 Provides Information to Shareholders of Catalyst Biosciences

Full year 2021 earnings released: US$2.87 loss per share (vs US$2.93 loss in FY 2020)

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian Singer Sends Letter to Catalyst Biosciences

Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency

Third quarter 2021 earnings released: US$0.80 loss per share (vs US$0.73 loss in 3Q 2020)

FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.96 loss in 2Q 2020)

Catalyst Biosciences Announces First Patient Screened for CFI Deficiency in Its CB 4332 Screening and Natural History of Disease Studies

Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from Russell 3000E Value Index

Catalyst Biosciences, Inc. Announces Initiation of Dosing in the Company's Phase 1/2 Study (MAA-202) of Marzeptacog Alfa

Catalyst Biosciences Announces the Dosing of the First Patient in the Crimson 1 Study, the Company's Phase 3 Registration Trial (Maa-304 - Crimson 1)

Revenue beats expectations

New 90-day high: €6.00

Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress

New 90-day high: €5.50

Catalyst Biosciences, Inc. Receives FDA Fast Track Designation for Subcutaneous Marzaa for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors

New 90-day high: €5.40

New 90-day low: €3.70

New 90-day low - €4.18

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera